©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Protein SIC, a Novel Extracellular Protein of Streptococcus pyogenes Interfering with Complement Function (*)

(Received for publication, August 16, 1995)

Per Åkesson (1)(§) Anders G. Sjöholm (2) Lars Björck (1)

From the  (1)Department of Cell and Molecular Biology, Section for Molecular Pathogenesis, and the (2)Department of Medical Microbiology, Lund University, Lund S-221 00, Sweden

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The human pathogen Streptococcus pyogenes possesses a chromosomal region, the mga regulon, that contains co-regulated genes important to the virulence of these bacteria. A novel gene located in the mga regulon of a S. pyogenes strain of serotype M1 was cloned and sequenced. It translates into a protein of 305 amino acid residues, including a signal sequence of 32 amino acids and a central region consisting of three tandem repeats. The sequence represents a novel structure with no significant homology to any previously published sequence. The protein was purified from the streptococcal culture media where it is present in substantial amounts. Affinity chromatography of human plasma on Sepharose coupled with the protein specifically adsorbed two plasma proteins which were identified as clusterin and histidine-rich glycoprotein (HRG). The interactions between the streptococcal protein and the plasma proteins were further characterized using purified clusterin and HRG. Inhibition experiments indicated that they have affinity for overlapping or closely located sites in the streptococcal protein. Both clusterin and HRG are regulators of the membrane attack complex (C5b-C9) of complement. When the streptococcal protein was added to serum, complement-mediated lysis of sensitized sheep erythrocytes and guinea pig erythrocytes was inhibited. In addition, the streptococcal protein was incorporated into C5b-C9 in serum, indicating the location of its action. The name, protein SIC, streptococcal inhibitor of complement-mediated lysis, is therefore suggested for this novel protein. The occurrence of protein SIC and its gene was investigated in a collection of S. pyogenes strains comprising 55 different M serotypes. Only M1 and M57 strains were positive in this screening, indicating that protein SIC could be a virulence determinant. Thus, during recent years, the M1 serotype has been connected with a world-wide increase of severe and toxic S. pyogenes infections.


INTRODUCTION

Streptococcus pyogenes is an important human pathogen causing a number of acute suppurative infections such as erysipelas, necrotizing fasciitis, and pharyngitis. These Gram-positive bacteria also cause a serious toxic shock-like syndrome, whereas glomerulonephritis and rheumatic fever are serious poststreptococcal sequelae. To elude the host defense and establish an infection, S. pyogenes has developed multiple molecular mechanisms. Some of these are dependent on genes of the mga regulon. The genes of this regulon are under the control of a positive regulator gene, previously called mry (Caparon and Scott, 1987) or virR (Simpson et al., 1990). According to a recent agreement, this regulator should now be called mga, multigene regulator of group A streptococcus.

Based on structural variations in the antiphagocytic M protein (for references, see Fischetti(1989) and Kehoe(1994)), S. pyogenes can be divided into more than 80 different serotypes. Since the late 1980s unusually severe S. pyogenes infections have been reported world-wide, infections which have predominantly been associated with the M1 serotype (for references, see Martin and Single (1993) and Musser et al.(1993)). This serotype is also connected with glomerulonephritis and rheumatic fever. The strain studied here, AP1, is of the M1 serotype. In AP1, the regulatory gene mga is followed by emm1, the gene for M1 protein. Immediately downstream of emm1 is sph (Åkesson et al., 1994), the gene encoding an IgGFc-binding M protein-related molecule called protein H (Gomi et al., 1990; Åkesson et al., 1990). Located adjacent to sph is a previously uncharacterized gene. This gene and its product are the subject of the present report. The data described imply that this extracellular protein, in the following referred to as protein SIC, plays a role in S. pyogenes pathogenicity and virulence through previously unknown molecular mechanisms.


EXPERIMENTAL PROCEDURES

Bacterial Strains, Bacteriophage, and Plasmids

Protein SIC and the sic gene were isolated from S. pyogenes strain AP1 (40/58) of the M1 serotype from the Institute of Hygiene and Epidemiology, Prague, Czech Republic. Forty-eight additional strains of different M serotypes were also obtained from this institute. These strains have been described (Ben Nasr et al., 1995). S. pyogenes strains of serotypes M3, M33, M42, M52, M61, and M67 were kindly provided by Dr. U. Sjöbring, Lund University, and a collection of 35 M1 strains isolated in Sweden 1980-89 were kindly provided by Dr. Stig Holm, Umeå University. One S. pyogenes strain of serotype M1 and two of type M57 were from the late Dr. L. W. Wannamaker. The sic gene was cloned from a EMBL3 clone described previously (Åkesson et al., 1994). Plasmid vectors pUC18/19 (Yanisch-Perron et al., 1985) and pK18/19 (Pridmore, 1987) were used in subcloning experiments. PCR (^1)products were cloned into the inducible secretion vector pHD389 (Dalböge et al., 1989). The Escherichia coli strain JM109 was used as host for recombinant plasmids. Streptococci were grown in Todd-Hewitt broth supplemented with 0.2% yeast extract and E. coli in LB broth.

Proteins and Antisera

Recombinant M1 protein, protein PAB, and streptococcal cysteine proteinase (SCP) were purified as described previously (Åkesson et al., 1994; de Château and Björck, 1994; Berge and Björck, 1995). Human serum albumin (HSA) was from Sigma. The monoclonal antibody MCaE11 directed against a neoantigen of polymerized C9 within the C5b-C9 membrane attack complex (MAC) of complement (Mollnes et al., 1985b) was kindly provided by Dr. T. E. Mollnes, The National Hospital, Oslo, Norway. Antisera against purified streptococcal protein SIC and SCP were raised in rabbits. Sheep anti-rat clusterin (polyclonal IgG fraction) cross-reacting with human clusterin was purchased from Quidel (San Diego, CA). Goat antisera against human histidine-rich glycoprotein (HRG) was a kind gift from Dr. William T. Morgan, University of Missouri, Kansas City, MO. Peroxidase-conjugated goat anti-rabbit IgG (Bio-Rad) and donkey anti-sheep IgG (ICN) were used as secondary antibodies.

Purification of Protein SIC

Streptococcal protein SIC was purified by growing AP1 bacteria to midlog phase (A = 0.5) and precipitating the culture supernatant with 30% ammonium sulfate. The resulting precipitate was resuspended to 1/100 of the starting volume with 20 mM Tris, pH 7.5, and dialyzed against the same buffer. This material was applied to a Mono Q column on a fast protein liquid chromatography system (Pharmacia, Uppsala, Sweden). Using a linear NaCl gradient, a single sharp peak was eluted at 0.3 M NaCl. Corresponding fractions were pooled, concentrated, and subjected to gel filtration chromatography on a Superose 12 column (Pharmacia) in PBSA (0.03 M phosphate, 0.12 M NaCl, 0.02% NaN(3), pH 7.2). Fractions containing the suspected protein SIC were pooled, and the identity of the protein was confirmed by NH(2)-terminal amino acid sequencing and later by Western blotting using antisera against protein SIC. The yield was 0.5-2 mg of purified protein SIC per liter of culture. Recombinant protein SIC was purified from an E. coli strain JM109 harboring the sic gene in pHD389. The strain was grown to midlog phase at 30 °C before inducing protein production by raising the temperature to 40 °C for 4 h. The culture supernatant was collected, and purification of protein SIC was performed as described above. In order to examine the presence of protein SIC in other group A streptococcal strains, cultures grown to midlogarithmic phase were precipitated with 30% ammonium sulfate. The precipitates were washed with ice-cold ethanol, dissolved in 100 µl of SDS-PAGE sample buffer, and subjected to Western blot analysis using rabbit antiserum against protein SIC.

Purification of Clusterin and HRG

For the purification of clusterin and HRG, citrated fresh human plasma supplemented with 1 mM benzamidine and 0.4 mM phenylmethylsulfonyl fluoride was used. Clusterin was purified by a method modified from a previous study (Wilson and Easterbrook-Smith, 1992). Thus, human plasma was differentially precipitated with polyethylene glycol (12-23%, w/v). The precipitate was then passed over an IgG-Sepharose column (Pharmacia Biotech Inc.). The column was washed with PBSA, and bound proteins were eluted with 0.1 M glycine-HCl, pH 2.0. The material was dialyzed against 20 mM Tris, pH 7.5, and subjected to a Mono Q column. Using a linear NaCl gradient, a protein peak eluted at 0.3 M NaCl was found to contain a single band of 80 kDa when analyzed by SDS-PAGE under nonreducing conditions. The material gave rise to a single band of 35 kDa when run under reducing conditions in the presence of 5% beta-mercaptoethanol. The bands were identified as clusterin in Western blot experiments using anti-clusterin antibodies. HRG was purified using the protocol of Saigo et al.(1989). Briefly, plasma was absorbed with CM-Sephadex (Pharmacia). The matrix was washed extensively with distilled water, and adsorbed proteins were eluted with 0.5 M NH(4)HCO(3). After dialysis against PBS, the material was applied to a HiTrap Heparin column (Pharmacia). The column was washed with PBS, and proteins were eluted with 1.0 M NaCl. The eluate was dialyzed against 20 mM Tris, pH 7.5, and subjected to ion exchange chromatography on a Mono Q column. A linear NaCl gradient was used, and the peak at 0.25 M NaCl was collected. The resulting preparation consisted of two major bands of 70 and 63 kDa when examined by SDS-PAGE under nonreducing conditions. The identity of the bands with HRG was confirmed by Western blotting using anti-HRG antisera.

Polymerase Chain Reactions

PCR was performed using Taq DNA polymerase (Promega). For amplification of the sic gene for cloning, primers S1 and S2 (Fig. 2), corresponding to base pairs (bp) 97-123 and bp 928-905 of the sic sequence (Fig. 1), were used. To investigate the occurrence of sic in other group A streptococcal isolates, PCR was performed with the S1 and S2 primer with an annealing temperature at 20 °C below the T(m) of the shortest primer (46 °C). Templates for the reactions were prepared by resuspending a single bacterial colony in 100 µl of water, vortexing the sample vigorously, and then boiling it for 5 min. Cell debris was removed by centrifugation, and 5 µl of the resulting supernatant were used in a 50-µl reaction. In order to determine the relationship of sic to other genes of the streptococcal mga regulon, PCRs with two different primer pairs outlined in Fig. 2were performed. In one reaction, the H1 primer corresponding to the conserved membrane anchoring motif of cell wall proteins of Gram-positive cocci; bp 1357-1381 of the sph sequence (Gomi et al., 1990) and the S2 primer corresponding to the end of the sic sequence were used. In another reaction, the S3 primer corresponding to bp 871-890 of the sic sequence (Fig. 1) and the C1 primer from the signal sequence of the C5a peptidase gene, bp 888-868 in the scpA sequence (Chen and Cleary, 1990), were used. Reactions were performed with AP1 chromosomal DNA as the template.


Figure 2: A map of the mga regulon in strain AP1 and a schematic outline of the structure of protein SIC. A region of the streptococcal chromosome containing genes of the mga regulon is depicted in the upper part of the figure. The relative location and size of the genes were determined by nucleotide sequencing and PCR (Gomi et al., 1990; Åkesson et al., 1994; B.-M. Kihlberg, J. Cooney, M. G. Caparon, A. Olsén, and L. Björck,(1995) Footnote 2). The location of oligonucleotide primers used for the PCR experiments in this work are marked with arrows. In the lower part of the figure, protein SIC and its domains are shown. Numbers below the schematic representation correspond to the first amino acid of these domains.




Figure 1: Nucleotide sequence and deduced amino acid sequence of the sic gene from S. pyogenes strain AP1. The first 188 nucleotides representing the sequence between the protein H gene (sph) and the sic gene and the first 131 nucleotides of the coding sequence have been published (Gomi et al., 1990). In this work, the sequence from nucleotide 7 in the coding sequence was determined. The start of the signal sequence (Ss), the NH(2)-terminal short repeat region (SRR), and the tandem repeats R1-R3 are indicated with arrows. The short repeats (I-V) are marked with bars. Possible -35 and -10 promoter sequences and the ribosomal binding site (RBS) are denoted with dashed lines.



Cloning Techniques and Sequence Determination

The PCR product amplified for the cloning of the sic gene was generated with primers containing recognition sites for NarI and XbaI. This fragment of 830 bp was purified, digested with NarI and XbaI, and cloned into pHD389 digested with the same enzymes. Standard cloning procedures were used (Sambrook et al., 1989). Restriction enzymes and T4 DNA ligase were from Promega. DNA sequencing was performed with Sequenase (Pharmacia) according to the manufacturer's instructions. Ordered sets of deletions in template plasmid DNA were prepared using exonuclease Bal31 (Promega). Computer search for sequence homology was made in the GenBank and EMBL data bases. Analysis of sequence data was performed using the GeneWorks program (IntelliGenetics, Mountain View, CA).

Electrophoresis and Electroblotting

SDS-PAGE was performed as described (Neville, 1971) using gels of 8% or 12% acrylamide content and 3.3% cross-linking. Before loading, samples were boiled for 3.5 min in an equal volume of buffer containing 2% SDS. Samples run under reducing conditions were boiled in the presence of 5% 2-mercaptoethanol. Western blotting was performed by transferring proteins to polyvinylidene difluoride (PVDF) membranes (Immobilon, Millipore) as described by Towbin et al.(1979). After blocking, membranes were incubated for 1 h with antisera against protein SIC (1:200, v/v), HRG (1:500, v/v), or antibodies toward clusterin (5 µg/ml), followed by a peroxidase-labeled secondary antibody (1:1000 v/v). For visualization of bound antibody, membranes were incubated in 0.02% (w/v) 3-amino-9-ethylcarbazol, 0.06% (v/v) H(2)O(2) in 50 mM sodium acetate buffer, pH 5.0.

Affinity Chromatography

In plasma absorption experiments, citrated fresh human plasma was mixed with the protease inhibitors benzamidine and iodoacetic acid to final concentrations of 5 mM each. 5 ml of undiluted plasma was immediately added to 1 mg of protein SIC coupled to Sepharose. After end to end rotation for 4 h at room temperature, the protein SIC-Sepharose was washed extensively with PBS (200 times the column volume), and the proteins bound to the column were eluted with 0.1 M glycine-HCl, pH 2.0. As a control, 5 ml of plasma was absorbed simultaneously with glycine-Sepharose. pH was adjusted to 7.5 by adding 1 M Tris, and the eluates were concentrated about 100-fold. Purified radiolabeled clusterin, HRG, or HSA (4 times 10^5 cpm in 1.0 ml of PBS) were run on columns of Sepharose coupled with protein SIC, M1 protein, or HSA. After washing with PBS, bound proteins were eluted with 0.1 M glycine-HCl, pH 2.0, and the radioactivity in the fractions was measured in a counter.

ELISA

Indirect ELISA (Engvall and Perlmann, 1971) was performed by coating microtiter plates (Maxisorb, Nunc, Denmark) overnight at 4 °C with serial dilutions of protein SIC (starting concentration 2 µg/ml). The plates were washed in PBST and incubated with clusterin (5 µg/ml) or HRG (1.25 µg/ml) diluted in PBST containing 1% gelatin (PBSTG). Bound proteins were detected by purified antibodies to clusterin (10 µg/ml) or antisera against HRG (1:2000, v/v), and binding was visualized by a horseradish peroxidase-conjugated secondary antibody against rabbit or sheep IgG (1:5000, v/v). All incubations were done at 37 °C for 1 h and followed by a washing step. Substrate solution, 0.1% (w/v) 2,2`-azinobis(3-ethylbenzthiazolinesulfonate), 0.012% (v/v) H(2)O(2) in 100 mM citric acid, 100 mM NaH(2)PO(4), pH 4.5, was added, and the change in absorbance at 405 nm was determined after 30 min.

A competitive ELISA was performed using the same procedure specified above except for the following: microtiter plates coated with either clusterin (1.5 µg/ml) or HRG (0.5 µg/ml) were incubated with a mixture of protein SIC (2 µg/ml for binding to clusterin; 1 µg/ml for binding to HRG) and serial dilutions of the competitor protein (starting concentration 20 µg/ml). Bound protein SIC was detected by a specific rabbit antisera (1:1000 v/v) followed by a secondary antibody toward rabbit IgG (1:3000 v/v) and 2,2`-azinobis(3-ethylbenzthiazolinesulfonate)/ H(2)O(2).

Binding of protein SIC to C5b-C9 complexes generated in serum was detected with a capture ELISA modified from Mollnes et al. (1985a). Microtiter plates were coated with 1.0 µg/ml MCaE11, a monoclonal antibody against a neoantigen of polymerized C9. Serum diluted 1/50 in PBSTG was added to the wells followed by serial dilutions of protein SIC or SCP (starting concentrations 10 µg/ml), and the plates were incubated for 3 h at room temperature. Diluted serum was also preincubated with protein SIC or SCP at various concentrations for 3 h, after which generation of C5b-C9 complexes was stopped by addition of EDTA at 10 mM. The incubation mixtures were then transferred to antibody-coated microtiter plates for analysis. Detection of protein SIC and SCP was performed as described above using specific rabbit antisera diluted 1/1000.

Complement-mediated Hemolytic Assays

Hemolytic assays in free solution were performed essentially as reported with target cells added in excess (Nilsson and Nilsson, 1984). Sheep erythrocytes, treated with rabbit antibody (NBL, Stockholm, Sweden) to yield optimally sensitized cells (EA), were used to measure classical pathway function. Assays were performed with Veronal-buffered saline (VBS) containing 0.15 mM Ca and 0.5 mM Mg. Alternative pathway-mediated hemolysis of guinea pig erythrocytes (GpE) was performed in VBS containing EGTA at a final concentration of 16 mM and Mg at 4 mM. Various quantities of protein SIC were added to human serum diluted to a concentration causing 10% lysis of erythrocytes. After incubation for 30 min at room temperature, EA or GpE were added at a concentration of 5 times 10^9 cells per ml and the mixture was incubated at 37 °C for 20 min. The reaction was stopped by adding a 15-fold volume of cold VBS containing 10 mM EDTA. After centrifugation, hemolysis was measured as the absorbance of the supernatant at 541 nm. The final human serum dilutions were 1:40 for assays of the classical pathway and 1:20 for the alternative pathway. The serum used was free from antibodies toward protein SIC. Complement-mediated hemolysis in gel was studied according to the procedure described by Truedsson et al.(1981) using EA or GpE in agarose as target cells. 5 µl of undiluted human serum and 1.5 µg (in 5 µl) of protein SIC or protein PAB were applied to adjacent wells in the gels with a distance of 2-4 mm. Additionally, 1.5 µg of bacterial proteins were added after 2, 4, 6, and 8 h of incubation. After incubation of the gels at 4 °C for 16 h, lysis was induced at 37 °C for 3 h.

Other Methods

NH(2)-terminal amino acid sequence analysis of proteins electrotransferred to PVDF membranes were performed on an Applied Biosystems 470A gas-liquid solid phase sequenator. Clusterin, HRG, and HSA were labeled with I using the Bolton and Hunter reagent (Amersham Corp., Buckinghamshire, United Kingdom). The specific activities were between 3 and 10 µCi per µg of protein.


RESULTS

Sequencing of the sic Gene

The previously reported sequence of the protein H gene (sph) revealed the first 138 bp of an open reading frame 188 bp downstream of the stop codon for sph (Gomi et al., 1990). To determine the structure of this possible downstream gene, a phage clone, 1:4 (Åkesson et al., 1994), harboring both the M1 gene (emm1) and sph was employed for subcloning. A 2.2-kbp SspI/EcoRI fragment of 1:4 that contained the open reading frame except for the first six nucleotides was cloned into the vector pUC19. Sequencing of this subclone revealed that the entire open reading frame was 915 bp encoding a putative amino acid sequence of 305 residues (Fig. 1). The first 32 amino acid residues represents a typical bacterial signal sequence including a positively charged NH(2)-terminal region, a hydrophobic core, and a polar cleavage region. The predicted mature protein has 273 amino acid residues and a calculated molecular mass of 30.677 kDa. The most characteristic feature of the sequence is a central repeat region consisting of three tandem repeats of 29, 29, and 21 amino acid residues each (R1-R3), showing 90-95% internal homology. The sequence preceding the R repeats also contains repeats although these are only five or nine amino acids long. In Fig. 1, five different repeats in this short repeat region (SRR) are indicated. They appear only twice each, and, except for repeat IV, they are not in tandem. Instead, some of the repeats are overlapping. The sequence located COOH-terminal of the R repeats is characterized by a high proline content, and, in a short stretch (residue 200-220), the prolines are evenly spaced every third or fourth residue. Computer-assisted analysis of the sequence predicted the protein to be highly hydrophilic with a pI of 4.2. A thorough search of the data bases with the entire sequence, or fragments of the sequence including all kinds of repeats, did not reveal any obvious homology either at the nucleotide or the amino acid level.

Location of sic in the mga Regulon of AP1

A further mapping of sic in the mga regulon of the AP1 strain was accomplished by PCR of chromosomal DNA with two sets of primers (Fig. 2). A reaction with the H1 primer corresponding to the sequence of M-like genes encoding the consensus membrane-anchoring motif (Fischetti et al., 1990) and the S2 primer corresponding to the 3` end of sic generated a fragment of 1.2 kbp. This confirms the intergenic distance of 188 bp between sph and sic as determined by sequencing. The PCR performed with the S3 primer from the 3` end of sic and the C1 primer corresponding to a part of the signal sequence of the C5a peptidase gene (scpA) generated a 2.2-kbp product. These experiments demonstrate that sic is located 188 bp downstream of sph and approximately 2.1 kbp upstream of scpA (Fig. 2).

Cloning and Expression of Protein SIC in E. coli and Purification of the Protein from Streptococcal Culture Medium

Oligonucleotides were constructed from the sic sequence to generate a PCR fragment corresponding to the mature protein. This fragment was amplified and cloned into the inducible expression vector pHD389. After growing the clone and inducing expression, a periplasmic lysate was examined by SDS-PAGE which showed the overexpression of a 34-kDa protein as compared to the host E. coli strain. Even higher amounts of the 34-kDa product were detected when analyzing the culture medium after precipitation with 80% ammonium sulfate. The protein was purified using precipitation of the culture medium with 30% ammonium sulfate, ion exchange chromatography, and gel filtration (Fig. 3B). The purified product was seen as a single band on SDS-PAGE, and the yield was about 5 mg of purified protein per liter of culture.


Figure 3: SDS-PAGE analysis of protein SIC after consecutive purification steps. The purification of the wild-type protein SIC from S. pyogenes is shown in A, and the purification of the recombinant protein from E. coli is shown in B. The material in lanes 1 was precipitated from culture medium with 80% ammonium sulfate followed by precipitation with 30% ammonium sulfate (lanes 2). Lanes 3 show protein SIC after an additional purification step on Mono Q, whereas the final product (lanes 4) was obtained after gel filtration on a Superose 12 column. Molecular mass markers are indicated.



Both the presence of a signal sequence and the absence of cell wall anchoring and membrane-spanning sequences in the gene suggested that the protein is secreted by streptococci of the AP1 strain. Consequently, a purification scheme similar to that used for the recombinant protein was applied to the culture medium of streptococcal AP1 bacteria, and a protein with identical migration on SDS-PAGE was obtained (Fig. 3A). The estimated amount of protein SIC in a 1-liter culture was 10-15 mg from which 1-2 mg of purified protein was obtained. NH(2)-terminal amino acid analysis of the protein showed that the first five amino acids (ETYTS) were identical with the start of the mature protein as indicated by the nucleotide sequence. Thus, the gene product of sic was shown to be expressed by the AP1 strain as an extracellular protein.

Absorption of Plasma Proteins with Immobilized Protein SIC

Being a secreted product, protein SIC is most likely active outside the bacterial cell. On the streptococcal chromosome, the sic gene is found in a regulon encoding proteins which interact with host molecules, particularly plasma proteins. In order to examine if protein SIC also has affinity for plasma proteins, the molecule was coupled to Sepharose and used to absorb human plasma. After extensive washing, the proteins bound to the protein SIC-Sepharose were eluted with glycine buffer, pH 2.0. The eluted material was lyophilized, resuspended in PBS at 50 times the concentration, and examined on SDS-PAGE. As seen in Fig. 4, two additional bands appeared as compared to the background pattern obtained after absorption with glycine-Sepharose. The bands were electroblotted onto a PVDF membrane, excised from the membrane, and subjected to NH(2)-terminal amino acid sequencing. The band of 80 kDa (labeled I in Fig. 4) showed the presence of two residues in equimolar yields after each sequencing cycle. The two sequences (DQTVSDNELQ and SLMPFSPYEP) were identical with the NH(2)-terminal sequences of the alpha and beta chains of the plasma protein clusterin (Jenne and Tschopp, 1989; Kirszbaum et al., 1989). The band of 70 kDa (labeled II in Fig. 4) had the sequence VSPTDCSAVE, identifying the protein as HRG (Koide et al., 1986). Plasma absorption experiments were performed with recombinant or streptococcal protein SIC coupled to Sepharose, and the same results were obtained.


Figure 4: SDS-PAGE analysis of proteins eluted from protein SIC-Sepharose after plasma absorption. Proteins eluted from glycine-Sepharose (lane A) or protein SIC-Sepharose (lane B) following incubation with human plasma. The samples were separated by SDS-PAGE (8%) under nonreducing conditions. Molecular mass markers are shown to the left. The bands of 80 kDa and 70 kDa in lane B are indicated with I and II, respectively.



Further Analysis of the Interaction between Protein SIC and the Plasma Proteins Clusterin and HRG

The binding of protein SIC to clusterin and HRG was now further analyzed. Firstly, clusterin and HRG were purified from human plasma. The observations made with human plasma were then re-examined by affinity chromatography of radiolabeled clusterin and HRG on protein SIC-Sepharose. About 30% of the I-clusterin and about 60% of the I-HRG were retained after chromatography on a protein SIC-Sepharose column. In contrast, less than 5% of iodine-labeled albumin was eluted from the column (Fig. 5). Additionally, less than 5% of I-clusterin or I-HRG was bound to columns of M1 protein or HSA-Sepharose (data not shown). The interactions were also tested by indirect ELISA in which the binding of clusterin or HRG to protein SIC was shown to be concentration-dependent (Fig. 6). Additionally, competitive ELISAs with clusterin or HRG as the coated proteins and protein SIC as the probe were performed. In these experiments, the binding of protein SIC to clusterin was blocked by HRG although less efficiently than by clusterin itself (Fig. 7A). Similarly, the binding of protein SIC to HRG was inhibited by clusterin (Fig. 7B). The results indicate overlapping or closely located binding sites for the two plasma proteins in protein SIC.


Figure 5: Affinity chromatography of radiolabeled proteins on protein SIC-Sepharose. 4 times 10^5 cpm in 1.0 ml of PBS of clusterin (A), HRG (B), or HSA (C) was applied to a protein SIC-Sepharose column. After washing with the application buffer, proteins bound to the column were eluted with 0.1 M glycine, pH 2.0. The radioactivity of the fractions was determined.




Figure 6: Binding of clusterin and HRG to protein SIC in indirect ELISA. Microtiter plates were coated with dilution series of protein SIC (bullet) or protein PAB (circle). 5 µg/ml clusterin (A) or 1.25 µg/ml HRG (B) were applied followed by specific antibodies to these proteins and a peroxidase-labeled secondary antibody. The absorption at 405 nm is presented in arbitrary units.




Figure 7: Competition for the binding of protein SIC to clusterin and HRG. Competitive ELISAs were performed on microtiter plates coated with 1.5 µg/ml clusterin (A) or 0.5 µg/ml HRG (B). Dilutions of clusterin (bullet), HRG (up triangle), or HSA (box) were mixed with an equivolume (100 µl) of protein SIC (2 µg/ml in A and 1 µg/ml B), and the mixtures were applied to the wells of the titer plates. Protein SIC bound to the immobilized proteins was detected with specific rabbit polyclonal antiserum followed by a peroxidase-labeled secondary antibody. The results are expressed as percent of protein SIC bound in the presence of a competitor relative to the specific binding in the absence of a competitor (100%).



Inhibition of Complement-mediated Hemolytic Activity by Protein SIC

Together with vitronectin, clusterin and HRG bind to the C5b-C9 complex in serum and thereby regulate the cytotoxic action of MAC (Tschopp et al., 1993; Chang et al., 1992). Clusterin partly inhibits hemolysis, while HRG modulates complement function in a biphasic fashion. To assess a possible role for protein SIC in classical pathway-mediated hemolysis, the protein was incubated with diluted human serum for 30 min at 20 °C prior to addition of EA. A dose-dependent inhibition of hemolysis was obtained (Fig. 8A). To exclude nonspecific degradation of complement components during preincubation of serum, an unrelated bacterial protein, the albumin-binding protein PAB of Peptostreptococcus magnus (de Château and Björck, 1994) was used as a negative control. The effect of protein SIC on alternative pathway-mediated hemolysis was examined using GpE as target cells in serum chelated with EGTA and supplemented with Mg. As shown in Fig. 8B, the effect of protein SIC on hemolysis of GpE was comparable to the effect on hemolysis of EA, consistent with interference at the C5b-C9 level. Similar results were obtained when effects of protein SIC were studied in hemolytic gels with EA and GpE as target cells (Fig. 8C). When protein SIC was applied adjacent to wells containing serum, the zone of lysis caused by serum was partly eclipsed. In contrast, protein PAB had no inhibitory effect on hemolysis.


Figure 8: Inhibition of complement-mediated hemolysis. Diluted human serum was incubated with various concentrations of protein SIC (bullet) or protein PAB (up triangle) followed by addition of sensitized sheep erythrocytes (A) or guinea pig erythrocytes (B). Hemolysis was measured by determining the absorbance of supernatants at 541 nm. Inhibition of lysis was calculated by dividing the absorbance with the value obtained when incubating serum with buffer (PBS). Data represent the mean from three separate experiments and ±S.E. is indicated. In C, 5 µl of undiluted human serum was applied to wells in agarose gels containing sensitized sheep erythrocytes (I) or guinea pig erythrocytes (II). Protein SIC or protein PAB were applied (6 µg) in the adjacent wells as indicated. Gels were incubated at 4 °C overnight and hemolysis was induced by incubation at 37 °C for 3 h.



Binding of Protein SIC to C5b-C9 Complexes

The interaction between protein SIC and the terminal complement proteins in serum was examined with a capture ELISA. In the first layer, a monoclonal antibody was used that detects an epitope of polymerized C9 that is formed during assembly of the C5b-C9 complex. Incubation of serum gives a high level of such complexes binding to the antibody due to spontaneous in vitro activation of complement (Mollnes et al., 1985a). In Fig. 9, an experiment is shown where serum and protein SIC simultaneously were added to and incubated with the solid-phase antibody. The amount of bound protein SIC was then measured. In contrast to the control protein, SCP, protein SIC is incorporated into the C5b-C9 complex generated in serum. No protein SIC binding was detected in the absence of serum or in serum containing EDTA. Further experiments were carried out to ensure that deposition of complement proteins due to activation by the immunoglobulin-coated microtiter plates (Zwirner et al., 1989) did not influence the results. Thus, serum was preincubated with protein SIC. After 3 h, EDTA was added and the incubation mixtures were transferred to the antibody-coated plates for analysis. The results obtained were virtually identical with those shown in Fig. 9.


Figure 9: Binding of protein SIC to C5b-C9 complexes. A monoclonal antibody directed against a neoantigen of polymerized C9 within C5b-C9 was used to coat microtiter plates (1 µg/ml). Dilution series of protein SIC (bullet) or SCP (up triangle) were mixed with human serum in a final dilution of 1:50 and applied to the wells. Incubation was also done with a dilution series of protein SIC in buffer (circle). Protein SIC and SCP were detected by specific antibodies to these proteins and a peroxidase-labeled secondary antibody.



Distribution of Protein SIC in Strains of S. pyogenes

A collection of 55 group A streptococcal strains of different M types were tested for the presence of the sic gene and the expression of protein SIC. At the DNA level, sic was identified by PCR using primers from the start of the coding sequence and the repeat regions and by performing the reaction under low stringency conditions. The expression of protein SIC was tested by growing the strains to midlogarithmic phase, precipitating the culture media with 30% ammonium sulfate, and examining the precipitate in a Western blot using polyclonal antisera against protein SIC. The strains of M types 1 and 57 were positive both in the PCR and in Western blot experiments. The rest of the strains gave no PCR products and were negative in the Western blot analyses. After the initial screening, 35 additional M type 1 isolates and two M type 57 strains were tested. All of these strains contained sic and expressed protein SIC. The results suggest that the sic gene is highly restricted among various M serotypes, whereas within these serotypes all isolates have and express the gene.


DISCUSSION

Analogous to other proteins encoded by genes under the control of mga, protein SIC contains repeated sequences. However, the sequence of protein SIC, including the repeats, shows no homology to previously sequenced genes. It is also noteworthy that in contrast to all other described products of the mga regulon, protein SIC does not have the typical structural features of cell wall proteins in Gram-positive bacteria; i.e. a COOH-terminal region anchored to the cell wall through an LPXTG motif (Fischetti et al., 1990; Schneewind et al., 1992, 1995), followed further toward the COOH terminus by a hydrophobic membrane-spanning domain and a tail of mostly positively charged amino acid residues. The missing cell wall anchor, the occurrence of a typical signal sequence, and the fact that considerable amounts of protein SIC are found in the growth medium suggest that the molecule is secreted and has extracellular function(s).

Previous work has demonstrated several interactions between components of the complement system and proteins encoded by genes of the mga regulon. Members of the M protein family (M protein, protein Arp, protein Sir, and protein H) have been reported to bind complement factor H, CD46, and/or the C4b-binding protein (Horstmann et al., 1988; Okada et al., 1995; Thern et al., 1995), (^2)three proteins with regulatory functions in the complement system. Furthermore, the C5a peptidase (Wexler et al., 1983), which can be released from the streptococcal cell wall by a cysteine proteinase produced by the bacteria (Berge and Björck, 1995), cleaves the C5-derived fragment C5a and destroys its chemoattractant activity for polymorphonuclear leukocytes (Wexler et al., 1985). In the present study, the specific interactions between protein SIC and the plasma proteins clusterin and HRG directed our attention to the final cytolytic step in the complement cascade. Clusterin is known to inhibit the hemolytic activity of complement by binding to MAC (Tschopp et al., 1993; Tschopp and French, 1994), whereas the influence of HRG on MAC is biphasic, inhibitory, or stimulatory, depending on the experimental conditions (Chang et al., 1992). As demonstrated in the present study, protein SIC was inhibitory to hemolysis in classical pathway as well as alternative pathway systems. Furthermore, protein SIC was shown to be incorporated into C5b-C9 complexes formed in serum. Although other mechanisms may also be considered, the findings suggest that the anticomplementary action of protein SIC is focused on the terminal cytotoxic functions of complement.

The metabolically inert erythrocyte is a very sensitive target for MAC whereas most pathogenic bacteria including streptococci are resistant to complement-mediated cytolysis. However, apart from its cytolytic activity, MAC also has proinflammatory effects by stimulating the production and release of inflammatory mediators such as reactive oxygen metabolites, metabolites of arachidonic acid, and cytokines (for references see Morgan(1989)). Bacterial products affecting the various functions of MAC, directly or indirectly, could therefore influence the host-parasite relationship. The molecular complexity necessary to establish and maintain this relationship makes it difficult to predict the consequences of any isolated interaction. However, in the case of pathogenic and virulent bacteria like S. pyogenes, the balance is disturbed, and there is circumstantial evidence (see below) that protein SIC may contribute to the imbalance of the host-parasite relationship in S. pyogenes infections.

To our knowledge, protein SIC is the first bacterial protein reported to interact with clusterin or HRG. Mycobacterium tuberculosis, however, selectively absorbs clusterin from human plasma, (^3)suggesting that this important human pathogen could express surface molecules with affinity for clusterin. As mentioned, glomerulonephritis represents a medically significant sequelae following infections with S. pyogenes. In these cases, certain M serotypes are more common, including the two protein SIC-producing serotypes M1 and M57 (Holm, 1988). In post-streptococcal glomerulonephritis, immunoglobulin deposits are found in the glomeruli. Interestingly, MAC is regarded as a mediator of glomerular injury in immune complex-related disease (Couser et al., 1985), and clusterin was found to be co-localized with MAC in biopsies from glomerulonephritic kidneys (French et al., 1992). Also, plasma depleted of clusterin (to <30%) enhanced proteinuria and deposition of MAC components in perfused kidneys (Saunders et al., 1994). The association of protein SIC to nephritogenic M serotypes, and its binding of clusterin in human plasma makes it interesting to test whether protein SIC can induce kidney damage in an animal model.

Since the late 1980s, a world-wide increase of hyperacute, toxic, and often lethal S. pyogenes infections has attracted public attention also (Nowak, 1994). These systemic infections have been associated particularly with streptococci of the M1 serotype, and the observation that all M1 strains tested, including isolates from Swedish patients with toxic and severe infections (Holm et al., 1992), carry and express the sic gene, supports the notion that protein SIC plays a role in pathogenicity and virulence. The present work and future studies on protein SIC may therefore clarify molecular mechanisms which could be used as targets to prevent and treat S. pyogenes infections.


FOOTNOTES

*
This work was supported by grants from Swedish Medical Research Council Projects 7480 and 7921, the Medical Faculty, Lund University, the Foundations of Kock and Österlund, High Tech Receptor AB, and Swedish Research Council for Engineering Sciences Project 123. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBank(TM)/EMBL Data Bank with accession number(s) X92968[GenBank].

§
To whom correspondence should be addressed: Dept. of Cell and Molecular Biology, Section for Molecular Pathogenesis, Lund University, P. O. Box 94, S-221 00 Lund, Sweden. Tel.: 46-46-222-4488; Fax: 46-46-157-756; Per.Akesson@medkem.lu.se.

(^1)
The abbreviations used are: PCR, polymerase chain reaction; EA, sheep erythrocytes sensitized with rabbit antibody; ELISA, enzyme-linked immunosorbent assay; GpE, guinea pig erythrocytes; HRG, histidine-rich glycoprotein; HSA, human serum albumin; IgGFc, constant region of IgG; MAC, membrane attack complex; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; PVDF, polyvinylidene difluoride; SCP, streptococcal cysteine proteinase; VBS, Veronal-buffered saline; bp, base pair(s); kbp, kilobase pair(s).

(^2)
Kihlberg, B.-M., Cooney, J., Caparon, M. G., Olsén, A., and Björck, L.(1995) Microb. Pathogen., in press.

(^3)
H. Miörner, personal communication.


ACKNOWLEDGEMENTS

We are grateful to Chun-Li Liu and Kristin Persson for excellent technical assistance.


REFERENCES

  1. Åkesson, P., Cooney, J., Kishimoto, F., and Björck, L. (1990) Mol. Immunol. 27, 523-531 [CrossRef][Medline] [Order article via Infotrieve]
  2. Åkesson, P., Schmidt, K.-H., Cooney, J., and Björck, L. (1994) Biochem. J. 300, 877-886 [Medline] [Order article via Infotrieve]
  3. Ben Nasr, A., Herwald, H., Müller-Esterl, W., and Björck, L. (1995) Biochem. J. 305, 173-180 [Medline] [Order article via Infotrieve]
  4. Berge, A., and Björck, L. (1995) J. Biol. Chem. 270, 9862-9867 [Abstract/Free Full Text]
  5. Caparon, M. G., and Scott, J. R. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 8677-8681 [Abstract]
  6. Chang, N.-S., Leu, R. W., Rummage, J. A., Anderson, J. K., and Mole, J. E. (1992) Blood 79, 2973-2980 [Abstract]
  7. Chen, C., and Cleary, P. P. (1990) J. Biol. Chem. 265, 3161-3167 [Abstract/Free Full Text]
  8. Couser, W. G., Baker, P. J., and Adler, S. (1985) Kidney Int. 28, 879-890 [Medline] [Order article via Infotrieve]
  9. Dalböge, H., Bech Jensen, E., Töttrup, H., Grubb, A., Abrahamson, M., Olafsson, I., and Carlsen, S. (1989) Gene (Amst.) 79, 325-332 [CrossRef][Medline] [Order article via Infotrieve]
  10. de Château, M., and Björck, L. (1994) J. Biol. Chem. 269, 12147-12151 [Abstract/Free Full Text]
  11. Engvall, E., and Perlmann, P. (1971) Immunochemistry 8, 871-874 [CrossRef][Medline] [Order article via Infotrieve]
  12. Fischetti, V. A. (1989) Clin. Microbiol. Rev. 2, 285-314 [Medline] [Order article via Infotrieve]
  13. Fischetti, V. A., Pancholi, V., and Schneewind, O. (1990) Mol. Microbiol. 4, 1603-1605 [Medline] [Order article via Infotrieve]
  14. French, L. E., Tschopp, J., and Schifferli, J. A. (1992) Clin. Exp. Immunol. 88, 389-393 [Medline] [Order article via Infotrieve]
  15. Gomi, H., Hozumi, T., Hattori, S., Tagawa, C., Kishimoto, F., and Björck, L. (1990) J. Immunol. 144, 4046-4052 [Abstract/Free Full Text]
  16. Holm, S. E. (1988) Acta Pathol. Microbiol. Scand. 96, 189-193
  17. Holm, S. E., Norrby, A., Bergholm, A.-M., and Norgren, M. (1992) J. Infect. Dis. 166, 31-37 [Medline] [Order article via Infotrieve]
  18. Horstmann, R. D., Sievertsen, H. J., Knobloch, J., and Fischetti, V. A. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 1657-1661 [Abstract]
  19. Jenne, D., and Tschopp, J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7123-7127 [Abstract]
  20. Kehoe, M. A. (1994) New Compr. Biochem. 27, 217-261
  21. Kirszbaum, L., Sharpe, J. A., Murphy, B., d'Apice, A. J. F., Classon, B., Hudson, P., and Walker, I. D. (1989) EMBO J. 8, 711-718 [Abstract]
  22. Koide, T., Foster, D., Yoshitake, S., and Davie, E. W. (1986) Biochemistry 25, 2220-2225 [Medline] [Order article via Infotrieve]
  23. Martin, D., and Single, L. A. (1993) J. Infect. Dis. 167, 1112-1117 [Medline] [Order article via Infotrieve]
  24. Mollnes, T. E., Lea, T., Froland, S. S., and Harboe, M. (1985a) Scand. J. Immunol. 22, 197-202 [Medline] [Order article via Infotrieve]
  25. Mollnes, T. E., Lea, T., Harboe, M., and Tschopp, J. (1985b) Scand. J. Immunol. 22, 183-195 [Medline] [Order article via Infotrieve]
  26. Morgan, B. P. (1989) Biochem. J. 264, 1-14 [Medline] [Order article via Infotrieve]
  27. Musser, J. M., Kapur, V., Kanjilal, S., Shah, U., Musher, D. M., Barg, N. L., Johnston, K. H., Schlievert, P. M., Henrichsen, J., Gerlach, D., Rakita, R. M., Tanna, A., Cookson, B. D., and Huang, J. C. (1993) J. Infect. Dis. 167, 337-346 [Medline] [Order article via Infotrieve]
  28. Neville, D. M., Jr. (1971) J. Biol. Chem. 246, 6328-6334 [Abstract/Free Full Text]
  29. Nilsson, U. R., and Nilsson, B. (1984) J. Immunol. Methods 72, 49-59 [CrossRef][Medline] [Order article via Infotrieve]
  30. Nowak, R. (1994) Science 264, 1665 [Medline] [Order article via Infotrieve]
  31. Okada, N., Liszewski, M. K., Atkinson, J. P., and Caparon, M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2489-2493 [Abstract]
  32. Pridmore, R. D. (1987) Gene (Amst.) 56, 309-312 [CrossRef][Medline] [Order article via Infotrieve]
  33. Saigo, K., Shatsky, M., Levitt, L. J., and Leung, L. L. K. (1989) J. Biol. Chem. 264, 8249-8253 [Abstract/Free Full Text]
  34. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  35. Saunders, J. R., Aminian, A., McRae, J. L., O'Farrel, K. A., Adam, W. R., and Murphy, B. F. (1994) Kidney Int. 45, 817-827 [Medline] [Order article via Infotrieve]
  36. Schneewind, O., Model, P., and Fischetti, V. A. (1992) Cell 70, 267-281 [Medline] [Order article via Infotrieve]
  37. Schneewind, O., Fowler, A., and Faull, K. F. (1995) Science 268, 103-106 [Medline] [Order article via Infotrieve]
  38. Simpson, W. J., LaPenta, D., Chen, C., and Cleary, P. P. (1990) J. Bacteriol. 172, 696-700 [Medline] [Order article via Infotrieve]
  39. Thern, A., Stenberg, L., Dahlbäck, B., and Lindahl, G. (1995) J. Immunol. 154, 375-386 [Abstract/Free Full Text]
  40. Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 4350-4354 [Abstract]
  41. Truedsson, L., Sjöholm, A. G., and Laurell, A.-B. (1981) Acta Pathol. Microbiol. Scand. Sect. C. Immunol. 89, 161-166
  42. Tschopp, J., and French, L. E. (1994) Clin. Exp. Immunol. 97, Suppl. 2, 11-14
  43. Tschopp, J., Chonn, A., Hertig, S., and French, L. E. (1993) J. Immunol. 151, 2159-2165 [Abstract/Free Full Text]
  44. Wexler, D. E., Nelson, R. D., and Cleary, P. P. (1983) Infect. Immun. 39, 239-246 [Medline] [Order article via Infotrieve]
  45. Wexler, D. E., Chenoweth, D. E., and Cleary, P. P. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 8144-8148 [Abstract]
  46. Wilson, M. R., and Easterbrook-Smith, S. B. (1992) Biochim. Biophys. Acta 1159, 319-326 [Medline] [Order article via Infotrieve]
  47. Yanisch-Perron, C., Vierra, J., and Messing, J. (1985) Gene (Amst.) 33, 103-119 [CrossRef][Medline] [Order article via Infotrieve]
  48. Zwirner, J., Felber, E., Reiter, C., Riethmüller, G., and Feucht, H. E. (1989) J. Immunol. Methods 124, 121-129 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.